May 16 (Reuters) - The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.


00


Reuters

17 Related Articles from 2018-05-16